Table 2 Adjusted incidence rate ratio (IRR) and score contribution of (A) use of corticosteroids, (B) start of azathioprine, (C) start of anti-TNF- α drugs, (D) need of surgery
From: A risk score system to timely manage treatment in Crohn’s disease: a cohort study
IRR | 95% CI | p | score | ||
|---|---|---|---|---|---|
A. Use of corticosteroids | |||||
No or CD intestinal lesions < 20 cm and no complications (ref) | 1 | 0 | |||
CD complications at SICUS | 1.86 | 1.04 | 3.34 | 0.04 | 1 |
CD intestinal lesions > 20 cm and no complications at SICUS | 3.38 | 1.80 | 6.35 | < 0.01 | 3 |
Presence of colon-ileal reflux at SICUS (ref) | 1 | 0 | |||
Absence of colon-ileal reflux at SICUS | 1.54 | 1.00 | 2.37 | 0.05 | 1 |
Age at diagnosis ≥40 years (ref) | 1 | 0 | |||
Age at diagnosis < 40 years | 1.83 | 1.04 | 3.24 | 0.04 | 1 |
B1 or B3 disease behavior (ref) | 1 | 0 | |||
B2 disease behavior | 2.23 | 1.26 | 3.93 | 0.01 | 2 |
Absence of specific symptoms at clinical assessment (ref) | 1 | 0 | |||
Presence of specific symptoms at clinical assessment | 1.93 | 1.36 | 2.73 | < 0.01 | 2 |
B. Start of azathioprine | |||||
Male (ref) | 1 | 0 | |||
Female | 2.08 | 1.19 | 3.64 | 0.01 | 1 |
BMI > 25 (ref) | 1 | 0 | |||
BMI < 21 | 4.10 | 1.95 | 8.61 | < 0.01 | 2 |
BMI 21–25 | 2.13 | 1.04 | 4.33 | 0.04 | 1 |
CDAI < 50 (ref) | 1 | 0 | |||
CDAI ≥50 | 1.82 | 1.13 | 2.90 | 0.013 | 1 |
C. Start of anti-TNF-α drugs | |||||
Absence of CD intestinal lesions or complications at SICUS (ref) | 1 | 0 | |||
CD intestinal lesions > 20 cm and no complications at SICUS | 5.72 | 1.88 | 17.40 | < 0.01 | 2 |
CD complications at SICUS | 2.34 | 0.81 | 6.73 | 0.12 | 1 |
Negative markers of inflammation (ref) | 1 | 0 | |||
Positive markers of inflammation | 2.63 | 1.45 | 4.78 | < 0.01 | 1 |
Absence of specific symptoms at clinical assessment (ref) | 1 | 0 | |||
Presence of specific symptoms at clinical assessment | 2.52 | 1.46 | 4.34 | < 0.01 | 1 |
D. Need of surgery | |||||
No previous surgery | 6.40 | 2.01 | 20.31 | < 0.01 | 2 |
Previous surgery and type of ileocolonic anastomosis (ICA) | |||||
• latero-lateral ICA (ref) | 1 | 0 | |||
• termino-terminal ICA | 3.90 | 0.62 | 24.69 | 0.15 | 2 |
No or CD intestinal lesions and no complications (ref) | 1 | 0 | |||
CD intestinal lesions > 0.5 cm and complications at SICUS | 10.63 | 3.04 | 37.11 | < 0.01 | 3 |
Corticosteroid at first flare (ref) | 1 | 0 | |||
No corticosteroid at first flare | 2.32 | 1.29 | 4.17 | 0.01 | 1 |
Absence of specific symptoms at clinical assessment (ref) | 1 | 0 | |||
Presence of specific symptoms at clinical assessment | 3.75 | 2.01 | 7.01 | < 0.01 | 2 |
No current use of corticosteroid (ref) | 1 | 0 | |||
Current use of corticosteroid | 3.60 | 1.99 | 6.51 | < 0.01 | 2 |
Negative markers of inflammation (ref) | 1 | 0 | |||
Positive markers of inflammation | 2.31 | 1.15 | 4.66 | 0.02 | 1 |